Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01745367 · ClinicalTrials.gov registry record · Phase 2
Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer
A Phase 2 study, sponsored by AVEO Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01745367 is a Phase 2 study that was terminated before completion, run by AVEO Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT01745367, a Phase 2 study, was terminated before completion, sponsored by AVEO Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a phase 2 multicenter, double-blind, randomized, placebo-controlled, two-arm study for subjects with locally recurrent or metastatic triple negative breast cancer.
Interventions
- DRUG Placebo
- DRUG paclitaxel
- DRUG Tivozanib Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01745367
The ClinicalTrials.gov registry entry for NCT01745367 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AVEO Pharmaceuticals, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01745367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01745367 about?
NCT01745367 is a clinical study titled "Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer". This is a phase 2 multicenter, double-blind, randomized, placebo-controlled, two-arm study for subjects with locally recurrent or metastatic triple negative breast cancer.
What is the current status of trial NCT01745367?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2012-11. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01745367?
The interventions under investigation include: Placebo (DRUG), paclitaxel (DRUG), Tivozanib Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01745367?
This trial is sponsored by AVEO Pharmaceuticals, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.